{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:24:33Z","timestamp":1786123473439,"version":"build-2736575974"},"reference-count":15,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100015632","name":"Moore Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015632","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2026,6]]},"abstract":"ABSTRACT<\/jats:title>\n \n Introduction<\/jats:title>\n \n Hairy cell leukemia (HCL) is an uncommon hematopoietic stem cell disease known to have an underlying somatic\n \n BRAF\n V600E<\/jats:sup>\n <\/jats:italic>\n driver mutation. Currently, the most accepted treatment is five or seven consecutive days of outpatient infusion of cladribine (e.g., continuous infusion), despite frequent antibiotic use and hospitalization with this regimen. As a result, a few investigators have adopted weekly infusion of cladribine with similar or improved results and fewer side effects.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n We conducted a retrospective, single\u2010institution cohort study of 36 treatment\u2010na\u00efve patients with HCL treated at the University of Colorado Hospital. Eighteen patients received intermittent weekly cladribine (intermittent cladribine [IC]) for 5\u20137 doses and 18 received standard daily cladribine (continuous cladribine [CC]) over 5\u20137 days. We report clinical cohort characteristics, response rates, progression\u2010free survival, overall survival, toxicity, hospitalization rates, and measurable residual disease monitoring in select patients using peripheral blood quantitative\n \n BRAF\n V600E<\/jats:sup>\n <\/jats:italic>\n PCR.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n We report here our experience with 18 patients with newly diagnosed\n BRAF<\/jats:italic>\n \u2010mutated HCL treated with weekly cladribine at a single institution compared to 18 HCL patients who received continuous infusions. Baseline hematologic parameters and overall survival were comparable between groups (\n p<\/jats:italic>\n \u00a0=\u00a00.1135), but there was a higher rate of complete remission for patients treated with IC (94.4%\u00a0vs. 61.1%) with significantly improved progression\u2010free survival (\n p<\/jats:italic>\n \u00a0<\u00a00.0001). We observed comparable rates of neutropenia, neutropenic fever, antibiotic use, and G\u2010CSF administration. There were fewer hospitalizations for patients treated with IC (4\/18) compared to patients treated with CC (6\/18). Rituximab exposure differed between groups, with 72% of patients in the IC cohort receiving rituximab compared with 27.2% in the CC cohort (although treatment status was documented for only 66.7% of patients in the CC cohort). Peripheral blood\n \n BRAF\n V600E<\/jats:sup>\n <\/jats:italic>\n allele burden significantly declined and correlated with clinical remission, but this was only performed in select patients who were treated in recent years.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n In this retrospective analysis, IC dosed weekly was associated with improved progression\u2010free survival and higher rates of complete remission compared to CC with comparable toxicity and fewer hospitalizations. These findings suggest a potential clinical benefit from this regimen. However, interpretation of these findings is limited by the non\u2010randomized design and differences in rituximab exposure between groups, which may have contributed to the observed outcomes and limited definitive conclusions.<\/jats:p>\n <\/jats:sec>\n \n \n Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission<\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/jha2.70311","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T10:56:17Z","timestamp":1779965777000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Weekly Cladribine Followed by Rituximab for the Treatment of Hairy Cell Leukemia"],"prefix":"10.1002","volume":"7","author":[{"given":"Jacqueline A.","family":"Turner","sequence":"first","affiliation":[{"name":"Division of Medical Oncology Department of Medicine University of Colorado School of Medicine Anschutz Medical Campus Aurora Colorado USA"},{"name":"Internal Medicine Residency Training Program Department of Medicine Mayo Clinic College of Medicine and Science Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Santos","sequence":"additional","affiliation":[{"name":"Internal Medicine Residency Training Program Department of Medicine University of Colorado School of Medicine \u00a0 Colorado USA"},{"name":"Division of Medical Oncology Department of Medicine Vanderbilt University Medical Center Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Pizzuti","sequence":"additional","affiliation":[{"name":"Internal Medicine Residency Training Program Department of Medicine University of Colorado School of Medicine \u00a0 Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Paton","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology Department of Medicine University of Colorado School of Medicine Anschutz Medical Campus Aurora Colorado USA"},{"name":"Internal Medicine Residency Training Program Department of Medicine Oregon Health Sciences University Portland Oregon USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Robinson","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology Department of Medicine University of Colorado School of Medicine Anschutz Medical Campus Aurora Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102025\u20101802"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv200"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010022\u201000702\u20109"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031298"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506583"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014209"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2015.09.005"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(84)91491\u20100"},{"key":"e_1_2_7_10_1","first-page":"443","article-title":"2\u2010Chlorodeoxyadenosine, a \u201cNovel\u201d Agent in the Treatment of Both Lymphoid and Myeloid Malignancies","volume":"77","author":"Lauria F.","year":"1992","journal-title":"Haematologica"},{"key":"e_1_2_7_11_1","first-page":"22","article-title":"Weekly Administration of 2\u2010Chlorodeoxyadenosine in Patients With Hairy\u2010Cell Leukemia Is Effective and Reduces Infectious Complications","volume":"84","author":"Lauria F.","year":"1999","journal-title":"Haematologica"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102006\u201008\u2010042929"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190903131755"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802527681"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102011\u201008\u2010371179"},{"key":"e_1_2_7_16_1","first-page":"309","article-title":"Long\u2010Term Follow\u2010Up of Front\u2010Line Treatment of Hairy Cell Leukemia With 2\u2010Chlorodeoxyadenosine","volume":"89","author":"Zinzani P. L.","year":"2004","journal-title":"Haematologica"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.70311","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jha2.70311","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.70311","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:53:29Z","timestamp":1786114409000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.70311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/jha2.70311"],"URL":"https:\/\/doi.org\/10.1002\/jha2.70311","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"2026-02-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70311"}}